Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC) - Kim, D-W; Tan, D S-W; Ponce Aix, S (J Clin Oncol, 2018)
, et al.